URMC Related Haplo-identical Donor BMT
NCT02660281
Completed
This study will be a single-center treatment protocol, designed to validate the process of related donor haploidentical-SCT at the Wilmot Cancer Institute Blood and Marrow Transplant Unit.
Gender:
ALL
Ages:
Between 6 months and 75 years
Trial Updated:
11/01/2021
Locations: Wilmot Cancer Institute, Rochester, New York
Conditions: Hematological Disease, Immune Deficiencies, Solid Tumors, Myelofibrosis, Multiple Myeloma, Lymphoma
Register for Updates
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
NCT01445535
Completed
Studies conducted at the National Cancer Institute suggest that certain chemotherapy drugs may be more effective if given by continuous infusion into the vein rather than by the standard method of rapid intravenous injection. One such combination of six chemotherapy drugs, known as Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, Rituximab (EPOCH-R), has had a high degree of effectiveness in people with certain kinds of cancer. Recent evidence also indicates that the effects of... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/28/2021
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell Lymphoma
Register for Updates
TBI Dose De-escalation for Fanconi Anemia
NCT00352976
Completed
This is a single arm, total body irradiation (TBI) trial. All patients will be prescribed TBI 300 cGy with the goal of evaluating secondary endpoints.
Gender:
ALL
Ages:
All
Trial Updated:
10/27/2021
Locations: University of Minnesota Medical Center, Minneapolis, Minnesota
Conditions: Fanconi Anemia
Register for Updates
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
NCT00000703
Completed
To determine the safety and effectiveness of a combination chemotherapy-radiation-zidovudine (AZT) treatment for patients with peripheral lymphoma. Other chemotherapies have been tried in patients with AIDS related lymphomas, but the results have not been satisfactory. This study will show whether the combination of chemotherapy, radiation, and AZT is more effective and less toxic than previously used treatments.
Gender:
ALL
Ages:
Between 19 years and 69 years
Trial Updated:
10/27/2021
Locations: Los Angeles County - USC Med Ctr, Los Angeles, California +13 locations
Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Register for Updates
A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
NCT00000899
Completed
The purpose of this study is to determine the safety of anti-HIV drugs combined with low-dose chemotherapy (consisting of cyclophosphamide \[CTX\]) in HIV-positive patients. This study examines whether this combination therapy can reduce the number of HIV-infected cells hidden in the lymph nodes and blood. Current anti-HIV drug treatments can greatly reduce the levels of HIV in the human body. However, HIV can hide in certain immune cells and escape the drugs' effects. Chemotherapy using CTX de... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/27/2021
Locations: Univ of North Carolina, Chapel Hill, North Carolina +1 locations
Conditions: HIV Infections
Register for Updates
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
NCT00000658
Completed
To determine the impact of dose intensity on tumor response and survival in patients with HIV-associated non-Hodgkin's lymphoma (NHL). HIV-infected patients are at increased risk for developing intermediate and high-grade NHL. While combination chemotherapy for aggressive B-cell NHL in the absence of immunodeficiency is highly effective, the outcome of therapy for patients with AIDS-associated NHL has been disappointing. Treatment is frequently complicated by the occurrence of multiple opportun... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
10/26/2021
Locations: USC CRS, Los Angeles, California +21 locations
Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Register for Updates
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
NCT00000689
Completed
To determine the toxicity and effectiveness of adding sargramostim (recombinant granulocyte-macrophage colony stimulating factor; GM-CSF) to a standard chemotherapy drug combination (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) known as mBACOD in the treatment of non-Hodgkin's lymphoma in patients who are infected with HIV. Treatment of patients with AIDS-associated lymphoma is achieving inferior results when compared with outcomes for non-AIDS patient... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
10/26/2021
Locations: USC CRS, Los Angeles, California
Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Register for Updates
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
NCT01421017
Completed
This study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I) and test the effectiveness of the combination treatment of IMQ, cyclophosphamide (CTX), and radiotherapy (RT) in patients with skin metastases from breast cancer in the second part (Phase II). Currently this trial is in its Phase II part.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/25/2021
Locations: New York University Medical Center, New York, New York
Conditions: Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Register for Updates
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
NCT00006669
Withdrawn
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to kill cancer cells. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of rituximab followed by combination chemotherapy in treating patients who have refractory or recurrent non-Hodgkin's lymphom... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/19/2021
Locations: Washington Cancer Institute, Washington, District of Columbia +1 locations
Conditions: Lymphoma
Register for Updates
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01412879
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy also work in different ways to kill more cancer cells or stop them from growing. It is not yet known whether rituximab is more effective with combination chemotherapy or bendamustine hydrochloride in treating patients wit... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/14/2021
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +203 locations
Conditions: Lymphoma
Register for Updates
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
NCT00326417
Completed
The purpose of the current study is to continue to optimize conditioning regimens in high-risk patients with severe aplastic anemia transplanted with marrow from HLA-compatible unrelated donors. Specifically, the study will determine whether the addition of fludarabine to the conditioning regimen previously described by Deeg et al. will permit a reduction in the CY dose, to a point where sustained hematopoietic engraftment and survival are maintained (or improved), while the frequency of major r... Read More
Gender:
ALL
Ages:
65 years and below
Trial Updated:
10/13/2021
Locations: Phoenix Children's Hospital, Phoenix, Arizona +21 locations
Conditions: Anemia, Aplastic
Register for Updates
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
NCT00412360
Completed
This study is a Phase III, randomized, open-label, multi-center, prospective study of single umbilical cord blood (UCB) transplantation versus double UCB transplantation in pediatric patients with hematologic malignancies.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
10/13/2021
Locations: University of Alabama, Birmingham, Alabama +37 locations
Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma
Register for Updates